Kissei gains Japanese rights to Vifor's hyperphosphataemia agent
This article was originally published in Scrip
Kissei has acquired Japanese rights to Vifor Pharma's iron oxyhydroxide product PA21 for the treatment of hyperphosphataemia in chronic renal failure patients undergoing dialysis.
You may also be interested in...
Pricing set somewhere down the middle as Moderna reaches deal with US government on initial supplies of its mRNA coronavirus vaccine.
Headquartered in both China and US, the new firm will help partners bring drugs to China and other Asian markets. Novavax licenses COVID-19 vaccine in Japan to Takeda, following previous week’s deal for the vaccine in India.
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.